PT2880053T - Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4 - Google Patents

Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4

Info

Publication number
PT2880053T
PT2880053T PT138352430T PT13835243T PT2880053T PT 2880053 T PT2880053 T PT 2880053T PT 138352430 T PT138352430 T PT 138352430T PT 13835243 T PT13835243 T PT 13835243T PT 2880053 T PT2880053 T PT 2880053T
Authority
PT
Portugal
Prior art keywords
ltbp4
growth factor
binding protein
tissue damage
transforming growth
Prior art date
Application number
PT138352430T
Other languages
English (en)
Original Assignee
Ikaika Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikaika Therapeutics Llc filed Critical Ikaika Therapeutics Llc
Publication of PT2880053T publication Critical patent/PT2880053T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT138352430T 2012-08-01 2013-08-01 Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4 PT2880053T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261678564P 2012-08-01 2012-08-01

Publications (1)

Publication Number Publication Date
PT2880053T true PT2880053T (pt) 2020-05-22

Family

ID=50025687

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138352430T PT2880053T (pt) 2012-08-01 2013-08-01 Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4

Country Status (15)

Country Link
US (10) US9873739B2 (pt)
EP (2) EP3711771A1 (pt)
AU (6) AU2013313282B2 (pt)
CA (1) CA2880649C (pt)
CY (1) CY1123029T1 (pt)
DK (1) DK2880053T3 (pt)
ES (1) ES2791778T3 (pt)
HK (1) HK1211307A1 (pt)
HR (1) HRP20200818T1 (pt)
HU (1) HUE049217T2 (pt)
PL (1) PL2880053T3 (pt)
PT (1) PT2880053T (pt)
RS (1) RS60318B1 (pt)
SI (1) SI2880053T1 (pt)
WO (1) WO2014039189A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3142750T3 (da) * 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
US20170232276A1 (en) * 2014-09-30 2017-08-17 Primegen Biotech, Llc Treatment of fibrosis using deep tissue heating and stem cell therapy
US10225675B2 (en) 2015-02-17 2019-03-05 Electronics And Telecommunications Research Institute Multichannel signal processing method, and multichannel signal processing apparatus for performing the method
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
BR112019017697A2 (pt) 2017-02-28 2020-04-07 Janssen Biotech Inc vacinas contra influenza baseadas em vetores de vírus adenoassociado (aav)
ES2971872T3 (es) 2017-02-28 2024-06-10 Univ Pennsylvania Vector de clado F de virus adenoasociado (AAV) y usos para el mismo
CA3124415A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
WO2024182358A1 (en) * 2023-02-27 2024-09-06 Dyne Therapeutics, Inc. Methods and compositions for inhibiting progression of intramuscular fibrosis

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5372807A (en) 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
US6465493B1 (en) 1999-04-09 2002-10-15 Smithkline Beecham Corporation Triarylimidazoles
TR200400621T2 (tr) 1999-07-20 2004-08-23 Pharmexa A/S GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
WO2001053350A1 (en) 2000-01-18 2001-07-26 Agresearch Limited Myostatin and mimetics thereof
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
JP2004517068A (ja) 2000-11-16 2004-06-10 スミスクライン・ビーチャム・コーポレイション 化合物
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2476654A1 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
MXPA04008150A (es) 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
EP1578928B1 (en) 2002-09-16 2010-03-17 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2510893C (en) 2002-12-20 2012-07-10 Amgen, Inc. Binding agents which inhibit myostatin
WO2004083241A2 (en) 2003-03-19 2004-09-30 Takeda Pharmaceutical Company Limited Btc-interacting proteins and use thereof
WO2005084699A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
EA014112B1 (ru) 2004-03-23 2010-10-29 Эли Лилли Энд Компани Моноклональное антитело к миостатину и способы его применения
EP3808845A1 (en) 2004-06-28 2021-04-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
PE20060729A1 (es) 2004-07-29 2006-08-12 Schering Plough Ltd Compuestos heterociclicos como moduladores o inhibidores de la actividad de miostatina
US7807159B2 (en) 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
JP2011528804A (ja) * 2008-07-18 2011-11-24 オラジェニックス，インコーポレイテッド 結腸直腸癌の検出及び治療のための組成物
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
FR2943249B1 (fr) 2009-03-18 2011-08-12 Genethon Utilisation de la decorine pour augmenter la masse musculaire
JP2012521199A (ja) 2009-03-23 2012-09-13 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 免疫応答を調節するための化合物および方法
CA2761248C (en) 2009-05-08 2023-03-14 Joseph Collard Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer

Also Published As

Publication number Publication date
EP2880053B1 (en) 2020-02-26
AU2024204925A1 (en) 2024-08-08
EP2880053A1 (en) 2015-06-10
AU2019222850A1 (en) 2019-09-19
PL2880053T3 (pl) 2021-01-11
SI2880053T1 (sl) 2020-08-31
AU2018200078A1 (en) 2018-01-25
HRP20200818T1 (hr) 2020-08-07
AU2013313282B2 (en) 2018-02-01
US20200385457A1 (en) 2020-12-10
EP2880053A4 (en) 2016-03-09
US20190256589A1 (en) 2019-08-22
WO2014039189A1 (en) 2014-03-13
AU2021200783A1 (en) 2021-03-04
DK2880053T3 (da) 2020-05-11
US9873739B2 (en) 2018-01-23
US20140037637A1 (en) 2014-02-06
US20220089717A1 (en) 2022-03-24
US20210238274A1 (en) 2021-08-05
US20190002557A1 (en) 2019-01-03
CY1123029T1 (el) 2021-10-29
US20240287171A1 (en) 2024-08-29
EP3711771A1 (en) 2020-09-23
HK1211307A1 (en) 2016-05-20
US20230235044A1 (en) 2023-07-27
AU2013313282A1 (en) 2015-02-26
AU2021200783B2 (en) 2022-10-06
EP2880053B8 (en) 2020-04-15
RS60318B1 (sr) 2020-07-31
CA2880649C (en) 2023-03-14
US20200123247A1 (en) 2020-04-23
AU2022271391A1 (en) 2022-12-15
CA2880649A1 (en) 2014-03-13
HUE049217T2 (hu) 2020-09-28
US20180134785A1 (en) 2018-05-17
ES2791778T3 (es) 2020-11-05

Similar Documents

Publication Publication Date Title
HK1211307A1 (en) Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) (ltbp4)
HK1231361A1 (zh) 視網膜假體
EP2579819A4 (en) IMPLANT COMPONENTS AND METHOD
RS62297B1 (sr) Prirodne kombinovane hormonske supstitucione formulacije i terapije
IL236358A0 (en) Combination formulas of natural hormone replacements and therapies
ZA201300243B (en) Surgical implant
EP2611401A4 (en) RETINAL PROSTHESIS
EP2642929A4 (en) SURGICAL IMPLANT
EP2538988A4 (en) METHOD FOR TISSUE-DECELULARIZATION
EP2621405A4 (en) REVERSIBLE DEVELOPABLE ARTIFICIAL CORNEA AND PROCEDURE FOR ITS IMPLANTATION
EP2533772A4 (en) METHOD AND COMPOSITIONS FOR WOUND HEALING
EP2558037A4 (en) EXPANDABLE SPINE IMPLANT
GB201011815D0 (en) Surgical implant
GB201400072D0 (en) Implant and implant system
EP2757999A4 (en) IMPLANT OF HARD FABRIC
GB201006527D0 (en) Femoral implant
IL225298A0 (en) Lamina grafting system
EP2846716B8 (en) Implant for fixation of first and second bones
EP2680787A4 (en) SURGICAL IMPLANT AND METHOD THEREOF
GB201005625D0 (en) Immunogenic proteins and compositions
GB201103423D0 (en) Immunogenic proteins and compositions
EP2881079A4 (en) HYBRID PROSTHESIS SYSTEM BY IMPLANT, AND IMPLANT
EP2958601A4 (en) ARTIFICIAL BONE FORMS AND BONE ACUTE COMPOSITIONS
IL223095A0 (en) Methods and compositions for treatment nf-kb-mediated and a7 integrin-suppressed diseases
PL2502577T3 (pl) Proteza do zapewnienia połączenia z kanałem anatomicznym